Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 3/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 2/20 | 0.30 |
| ▸ | RARG | P13631 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027768 | 0.81 | RXRA (0.35) | HPGDHSD17B10RXRARARBRARG | |
| SCHEMBL11158693 | 0.77 | FTO (0.56) | FTOHPGDTSHRHSD17B10RXRA | |
| SCHEMBL4460410 | 0.73 | FTO (0.51) | FTOHPGDTSHRHSD17B10RXRA | |
| SCHEMBL8014576 | 0.73 | FTO (0.51) | FTOHPGDTSHRHSD17B10RXRA | |
| SCHEMBL6027643 | 0.71 | OPRM1 (0.36) | — | |
| SCHEMBL6027714 | 0.68 | RXRA (0.33) | RXRA | |
| SCHEMBL11157334 | 0.67 | FTO (0.46) | FTOHPGDTSHRHSD17B10RXRA | |
| SCHEMBL6027545 | 0.67 | RXRA (0.32) | RXRA | |
| SCHEMBL6027518 | 0.66 | NPSR1 (0.32) | — | |
| SCHEMBL20412704 | 0.66 | NPSR1 (0.32) | RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643993-A2 | SUBSTITUTED ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS, CANCER AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | disclosed |
| WO-2004093809-A2 | SUBSTITUTED ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS, CANCER AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | HSD17B10, IDH2, INSR | FTO 2911/4885HPGD 265/4885TSHR 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.